You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 Exon 20 Insertion Mutations

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

Terminated
  • NSCLC, Stage IV
  • +7 more
  • tarloxotinib bromide
  • Irvine, California
  • +13 more
Nov 11, 2021

NSCLC Trial in Winter Haven (Poziotinib, Docetaxel)

Suspended
  • NSCLC
  • Winter Haven, Florida
    Bond Clinic, P.A.
Jan 27, 2023

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

NSCLC Trial in Worldwide (Afatinib)

Completed
Has Results
  • NSCLC
  • Köln, Germany
  • +4 more
Aug 23, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

A Chart Review Study of Adults With Advanced NSCLC

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Aug 1, 2022

    NSCLC Trial in Changsha (BEBT-109)

    Completed
    • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 20, 2023

    Locally Advanced or Metastatic NSCLC, EGFR Exon20 Insertion Mutations Trial (JMT101, Osimertinib Mesylate Tablets)

    Not yet recruiting
    • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • EGFR Exon20 Insertion Mutations
    • JMT101
    • Osimertinib Mesylate Tablets
    • (no location specified)
    Nov 12, 2021

    EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

    Recruiting
    • EGFR Exon 20 Mutation
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 12, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Non-small Cell Lung Cancer EGFR Exon 20 Insertion

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
      • Cordoba, Andalucia, Spain
      • +14 more
      Nov 1, 2022

      Non Small Cell Lung Cancer, EGFR Exon 20 Mutation Trial in Worldwide (CLN-081)

      Recruiting
      • Non Small Cell Lung Cancer
      • EGFR Exon 20 Mutation
      • Duarte, California
      • +18 more
      Nov 11, 2022

      NSCLC Trial in Worldwide (Poziotinib)

      Active, not recruiting
      • NSCLC
      • Phoenix, Arizona
      • +62 more
      Jan 27, 2023

      NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +14 more
      • Glendale, California
      • +12 more
      Feb 2, 2023

      Metastatic NSCLC Trial (Amivantamab)

      Approved for marketing
      • Metastatic Non-Small Cell Lung Cancer
      • (no location specified)
      Jun 28, 2021

      Osimertinib for Patients With Non-Small Cell Lung Cancer

      Not yet recruiting
      • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
      • EGFR Exon20 Insertion Mutations
      • Baoding, China
      • +23 more
      Aug 23, 2022

      Advanced/Metastatic NSCLC (NSCLC) Trial in China (YK-209A tablet, Pemetrexed+carboplatin/Cisplatin)

      Not yet recruiting
      • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
      • Bengbu, Anhui, China
      • +51 more
      Mar 11, 2023

      NSCLC (NSCLC) Trial (TAK-788, Antidiarrheal prophylaxis)

      Withdrawn
      • Non-Small Cell Lung Cancer (NSCLC)
      • (no location specified)
      Dec 15, 2020

      Solid Tumor Trial in Worldwide (BDTX-189)

      Terminated
      • Solid Tumor
      • Scottsdale, Arizona
      • +37 more
      Oct 13, 2022

      Non-small-cell Lung Cancer Trial in Shanghai (pyrotinib combined with thalidomide)

      Recruiting
      • Non-small-cell Lung Cancer
      • pyrotinib combined with thalidomide
      • Shanghai, China
        Department of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
      Jan 26, 2021

      NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +13 more
      • furmonertinib 240 mg
      • +2 more
      • Yuma, Arizona
      • +37 more
      Dec 14, 2022